Notably, patients with MDS resistant to DNMTi showed elevated levels of PD-L1, PD-L2, and CTLA-4, suggesting a putative involvement of PD-1 signalling in resistance mechanisms to hypomethylating agents [124]. The gene discussed is PDCD1; the disease is myelodysplastic syndrome.